Scienture Holdings SCNX 深 沪
交易中 10-06 09:54:00 美东时间
3.357
-0.353
-9.51%
华盛通- 最 高4.25
- 今 开3.23
- 成交量 8.28万股
- 最 低 0.1339
- 昨 收 3.71
- 总市值 0
- 52周最高 4.25
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.1339
- 委 比 90.27%
- 总股本 --
- 历史最高 44.56
- 量 比 0.14
- 振 幅 110.95%
- 历史最低 0.1339
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
10-02 19:46
SCIENTURE To Provide REZENOPY To Addiction Treatment Centers
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United StatesAccording to IQVIA data
09-22 20:16
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.
07-10 16:27
Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing
https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view
04-28 01:05
SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
04-15 20:15
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.
03-30 19:46
SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development,
02-03 21:21
SCIENTURE HOLDINGS Collaborates With BlinkRx For Expanded Patient Access To Arbli.
U.S. Losartan market totals $245M annually with 71M prescriptions U.S. Losartan market totals $245M annually with 71M prescriptions
2025-12-10 21:07
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Scienture's Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.
2025-11-13 20:50
Scienture Holdings Announces Cancelation of ELOC
SCIENTURE HOLDINGS, INC. terminated its equity line of credit and deregistered 310,488 unsold shares to focus on the upcoming commercial launch of its first FDA-approved product, Arbli™, a ready-to-use oral liquid losartan for hypertension, stroke prevention, and diabetic nephropathy.
2025-06-17 12:05
